CoChat

Updated efficacy of the MEK inhibitor trametinib (T), BRAF inhibitor dabrafenib (D), and anti-EGFR antibody panitumumab (P) in patients (pts) with BRAF V600E mutated (BRAFm) metastatic colorectal cancer (mCRC).

Atreya, Chloe Evelyn, Van Cutsem, Eric, Bendell, Johanna C., Andre, Thierry, Schellens, Jan H. M., Gordon, Michael S., McRee, Autumn Jackson, O'Dwyer, Peter J, Muro, Kei, Tabernero, Josep, van Geel, Robin, Sidhu, Roger, Greger, James G, Rangwala, Fatima A., Motwani, Monica, Wu, Yuehui, Orford, Keith W., Corcoran, Ryan Bruce · 2015 · Journal of Clinical Oncology
Cited by 62

The DOI matches its Crossref record.

Abstract

103 Background: BRAF V600E mutations occur in 5–10% of mCRC and confer a poor prognosis. Unlike BRAFm melanoma, BRAF and MEK inhibitors have minimal activity in BRAFm mCRC. Preclinical data suggest that combined inhibition of the EGFR and MAPK pathways is required to maximally inhibit growth of BRAFm mCRC. This study evaluates the activity of the combination of P with D and/or T in BRAFm mCRC. Methods: Eligible pts with BRAFm mCRC received doublet, D+P or T+P, or triplet, D+T+P. Results: Doublet (D+P): 20 pts received the full doublet dose (D 150mg twice daily [BID] + P 6mg/kg every 2 weeks [Q2W]). Triplet: 35 pts received D+T+P including 24 pts that received full triplet dose (D 150mg BID + T 2mg once daily [QD] + P 6mg/kg Q2W). No dose-limiting toxicities were observed. As of October 20, 2014, the most common adverse events were dermatitis acneiform (Grade [G] 1/2 55%) and fatigue (G 1/2 45%) for D+P, and diarrhea (G1/2 60%, G3 9%) and dermatitis acneiform (G1/2 47%; G3 9%) for triplet. The confirmed response rate for D+P was 10% and for D+T+P was 26% (Table 1). Treatment with either regimen reduced levels of pERK in on-treatment biopsies relative to pre-dose biopsies (median reduction D+P 23%; D+T+P 54%). Pts are currently being enrolled to T+P. Updated results including progression-free survival and duration of response will be presented. Conclusions: Encouraging clinical activity with acceptable tolerability is seen with the triplet D+T+P in BRAFm mCRC. Clinical trial information: NCT01750918.Investigator–assessed best response with confirmation (RECIST 1.1). D 150 mg BID+ P 6mg/kg Q2W N = 20 D 150 mg BID, T 1.5 mg QD, P 4.8 mg/kg Q2W N = 3 D 150 mg BID, T 2 mg QD, P 4.8 mg/kg Q2W N = 4 D 150 mg BID, T 1.5 mg QD, P 6 mg/kg Q2W N = 4 D 150 mg BID, T 2 mg QD, P 6 mg/kg Q2W N=24 D+T+P Total N = 35 Complete response, n (%) 1 (5) 0 1 (25) 0 0 1 (3) Partial response, n (%) 1 (5) 2 (67) 1 (25) 0 5 (21) 8 (23) Stable disease, n (%) 16 (80) 1 (33) 2 (50) 2 (50) 15 (63) 20 (57) Progressive disease, n (%) 2 (10) 0 0 2 (50) 3 (13) 5 (14) Not evaluable, n (%) 0 0 0 0 1 (4) 1 (3) Response rate (CR+PR), n (%) 2 (10) 2 (67) 2 (50) 0 5 (21) 9 (26) 95% confidence interval, % 1.2–31.7 9.4–99.2 6.8–93.2 0.0–60.2 7.1–42.2 12.5–43.3

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2015.33.15_suppl.103

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 62

Metadata

Authors
Atreya, C. E., Van Cutsem, E., Bendell, J. C., Andre, T., Schellens, J. H. M., Gordon, M. S., McRee, A. J., O'Dwyer, P. J., Muro, K., Tabernero, J., van Geel, R., Sidhu, R., Greger, J. G., Rangwala, F. A., Motwani, M., Wu, Y., Orford, K. W., & Corcoran, R. B.
Venue
Journal of Clinical Oncology
Published
2015-05-20
Volume
33
Issue
15_suppl
Pages
103-103
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2599487961
Cited by
62
References
0
Type
conference abstract
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Updated efficacy of the MEK inhibitor trametinib (T), BRAF inhibitor dabrafenib (D), and anti-EGFR antibody panitumumab (P) in patients (pts) with BRAF V600E mutated (BRAFm) metastatic colorectal cancer (mCRC). https://app.cochat.ai/papers/10.1200/jco.2015.33.15_suppl.103
The paper
Atreya, C. E., Van Cutsem, E., Bendell, J. C., Andre, T., Schellens, J. H. M., Gordon, M. S., McRee, A. J., O'Dwyer, P. J., Muro, K., Tabernero, J., van Geel, R., Sidhu, R., Greger, J. G., Rangwala, F. A., Motwani, M., Wu, Y., Orford, K. W., & Corcoran, R. B. (2015). Updated efficacy of the MEK inhibitor trametinib (T), BRAF inhibitor dabrafenib (D), and anti-EGFR antibody panitumumab (P) in patients (pts) with BRAF V600E mutated (BRAFm) metastatic colorectal cancer (mCRC). Journal of Clinical Oncology. https://doi.org/10.1200/jco.2015.33.15_suppl.103

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.